Tagged with oncology

Switzerland Michael Cobas Meyer of Eli Lilly Switzerland reveals how these are very exciting times for the company, particularly given an extremely rich pipeline in the areas of diabetes, oncology and bio-medicines; how the challenge will be to transition from their existing portfolio to new products; and why Lilly´s focus is…

Slovakia Dr. Natasa Klicko, General Manager of Roche Slovakia, outlines the challenges and opportunities for the company in the country; their strategy of going “beyond the pill” to partner with and provide value to all healthcare stakeholders; the importance of data and methodology in the debate on market access; and Slovakia…

Mexico Mayra Galindo Leal, general director of the Mexican Association of the Fight Against Cancer (AMLCC) provides an overview of the main milestones of this association that stands as the most important patient organization for cancer in Mexico, her expectations towards the pharmaceutical industry, and the main challenges she faces when…

Switzerland As the home market, Switzerland and Roche’s Swiss pharma operations play an important and pioneering role within Roche’s global organization, with early patient access to innovation and new commercial models taking place in the country. The working title of the Healthcare & Life Science Review Switzerland is “A Leader Among…

Luxembourg Marc Diederich, Director of the LBMCC and principal investigator conducting independent research, leading and training a 25-person group including PhD and MSc students, runs us through the raison d’être of the Laboratory, how it is dedicated to the study of the cell and molecular biology of cancer and is focused…

Mexico Karel Fucikovsky, general director PFM Latin America at Pierre Fabre, on the strategic focus of the company on operational and commercial excellence in Mexico and Latin America, which both stand as strategic areas for the international growth of the group. He also highlights the main growth opportunities and market challenges the…

Biotech Ronald Scott, CEO of Basilea, a biotech company that was spun out of Roche in 2000, talks about launching its first two products, Zevtera and Cresemba; the milestone agreement with the Biomedical Advanced Research and Development Authority (BARDA) to develop Zevtera for the US market; and about the company’s partnering…

Pharma Olaf Weppner, General Manager of AbbVie Switzerland, highlights AbbVie’s intended foray into oncology, the importance of immunology to the group, the challenges and opportunities of the Swiss market and his own motivations for working in the industry. Mr. Weppner, you were appointed General Manager of AbbVie Switzerland less than a…

Pharma Raul Vivar, recently appointed GM of Eisai Mexico, describes the main achievements of the Japanese company in Mexico, the challenges that innovative companies face entering the Mexican market, and  the development path he will follow in order to foster growth. You took over the helm of the Mexican affiliate of…

Pharma Sandoz’s ambitious strategy in Mexico includes aggressive product launches in biosimilars and oncology, a heightened focus on the institutional market, and an awareness of inorganic growth opportunities. GM Mariano de Elizalde reveals the key pillars that will drive the affiliate to new heights. In Mexico, generics make up 79 percent…

Healthcare The President of the Doctoral Council of Semmelweis University, Dr. József Timár provides an overview of the healthcare system in Hungary with particular reference to oncology and describes the challenges and prospects of medical innovation in the country. Can you please provide an insight into the history and presence of…

Pharma György Bodoky, Head of the Oncology Department at Unified Szent István and Szent László Hospital, shares his insights on the state of oncological care in Hungary, the current effects of budget constraints as well his work founding the Hungarian Society of Clinical Oncology. As an introduction to our readers could…